-+ 0.00%
-+ 0.00%
-+ 0.00%
Jaguar Health Q3 2026 net loss narrows 40% year over year to $5.83 million
Share
Listen to the news
Jaguar Health Q3 2026 net loss narrows 40% year over year to $5.83 million
  • Jaguar Health’s third-quarter 2026 net loss narrowed 40% year over year to $5.83 million.
  • Total net revenue fell 24% year over year to $2.34 million.
  • Product revenue dropped 82% year over year to $551,000 following the licensing of Mytesi and Canalevia-CA1 to Future Pak.
  • The Future Pak agreement supports a strategic focus on developing crofelemer powder for rare diseases related to intestinal failure.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611160900ACCESSWRNAPR_____1251117) on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending